Screening for Breast Cancer; recommendations from
medical societies and boards.
1. US Preventive Services Task Force
(USPSTF)
In 2009, in light of evidence that
the benefit-risk ratio is higher among women older than 50 years and with less
frequent screening, the USPSTF
reversed its previous recommendation of mammography every 1 to 2 years
beginning at age 40 years and recommended routine screening every 2 years
starting at age 50. This was consistent with recommendations in many European
countries.
The USPSTF stated that “the decision to start regular, biennial
screening mammography before the age of 50 years should be an individual one
and take into account patient context, including the patient’s values regarding
specific benefits and harms.”
2. American Cancer Society
·
Yearly mammograms
are recommended starting at age 40 and continuing for as long as a woman is in
good health
· Clinical breast exam (CBE) about every
3 years for women in their 20s and 30s and every year for women 40 and over
· Women should know how their breasts
normally look and feel and report any breast change promptly to their health
care provider. Breast self-exam (BSE) is an option for women starting in their
20s.
Some women because of their family
history, genetic mutations, or other factors, MRI should be added to their screening. The number of women who fall into this category
is small: less than 2% of all the women in the US.
3. Swiss Medical Board
In January 2013, the SwissMedical Board, an independent health technology assessment initiative under
the auspices of the Conference of Health Ministers of the Swiss Cantons, the
Swiss Medical Association, and the Swiss Academy of Medical Sciences, was
mandated to prepare a review of mammography screening.
Based on existing literature the board recommended that no new
systematic mammography screening programs be introduced and that a time limit
be placed on existing programs. In addition, it stipulated that the quality of
all forms of mammography screening should be evaluated and that clear and
balanced information should be provided to women regarding the benefits and harms
of screening.
The Swiss Medical Board is nongovernmental body, and its
recommendations are not legally binding.
References:
This comment has been removed by the author.
ReplyDeleteLifeVoxel.AI platform offers a better alternative for the medical imaging community. Its unique approach is based on 12 international patents that encompass critical patient-centric delivery of care using intuitive, diagnostic and instantly accessible visualizations over the Internet. It works 100X faster and 42-80% cheaper than all our competitors.
ReplyDeleteRIS PACS Solution Interactive Streaming and Artificial Intelligence Platform